Abstract
We employed the polyclonal anti-p53 antibody NCL-CM1 to cultured cells and pathological tissues in order to investigate the expression of p53 oncoprotein in human malignant melanomas. The results in the cultured cells showed that the antigenic determinant was sensitive to formalin fixation, resulting in a lower reactivity than with fixation by alcohol. In pathological tissues, the expression of p53 oncoprotein increased with progression of the tumour. Among 79 melanomas 37 (47%) showed distinct nuclear labelling and the highest proportion of reactive cells was observed in metastatic melanomas (mean 4.8%). An immunocytochemical study also revealed the presence of mutant-type oncoprotein in human melanoma cell lines, which was recognized by monoclonal antibody P240, and we confirmed that the molecular weight of the antigens recognized by both antibodies was 53 kDa by Western blot analysis. Therefore, although the presence of point mutations in human melanomas is yet to be confirmed our data suggest that the antigen detected by NCL-CM1 is a mutanttype or a complex of mutant and wild-type p53 oncoproteins. This antibody may be useful in retrospective studies of tumours of melanocytic origin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akslen LA, Morkve O (1992) Expression of p53 in cutaneous melanoma. Int J Cancer 52:13–16
Barbareschi M, Girlando S, Mauri FA, Arrigoni G, Laurino L, Palma PD, Douglioni C (1992) Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol 166:343–350
Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a spectrum of human malignancies. Oncogene 6:1699–1703
Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RCG, Neoptolemons J, Williamson RCN, Lane DP, Lemoine NR (1991) Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64:1076–1082
Caamano J, Ruggeri B, Momiki S, Sickler A, Zhang SY, Klein-Szsnto AJP (1991) Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol 139:839–845
Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsp-70-p53 complex with an altered half life. Mol Cell Biol 8:531–539
Gannon JV, Greeves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 5:1595–1602
Harris AL (1991) Telling changes of base. Nature 350:377–378
Hiyoshi H, Matsuno Y, Kato H, Shimosato Y, Hirohashi S (1992) Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn J Cancer Res 83:101–106
Iggo R, Gatter K, Bartek J, Lane D, Harris A (1990) Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675–679
Iida K, Horikoshi T, Onodera H, Takahashi M, Kageshita T (1990) Ocular malignant melanomas: immunohistochemical characterization and prognosis. (in Japanese) Skin Cancer 5:171–175
Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S (1991) Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82:835–840
Lane DP, Crawford LV (1979) T-antigen is bound to a host protein in SV40 transformed cells. Nature 278:261–253
Maynard KR, Parsons PG (1986) Cross-sensitivity of methylating agents, hydroxyurea and methotrexate in human tumor cells of mer− phenotype. Cancer Res 46:5009–5013
Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C, Klein B (1992) Mutation of the p53 gene in human myeloma cell lines. Oncogene 7:1015–1018
Midgley CA, Fisher CJ, Bartek J, Voltesek B, Lane D, Barnes DM (1992) Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed inEscherichia coli. J Cell Sci 101:183–189
Natali PG, Bigotti A, Nicotra MR, Nardi R, Delovu A, Segatto O, Ferrone S (1989) Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Cancer Res 49:1269–1274
Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, Lennard TJ, Angus B, Horne HW (1991) p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164:75–81
Palyi I (1989) Heterogeneity of the response to inducers of differentiation and to cytostatics of tumor cell populations. Pathol Res Pract 183:11–17
Peris K, Cerroni L, Chimenti S, Soyer HP, Kerl H, Hofler H (1991) Proto-oncogene expression in dermal naevi and melanomas. Arch Dermatol Res 283:500–505
Pope JH, Morrison L, Moss DJ, Parsons PG, Mary R (1979) Human malignant melanoma cell lines. Pathology 11:191–195
Porter PL, Gown AM, Kramp SG, Coltrera MD (1992) Wide-spread p53 overexpression in human malignant tumors: an immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 140:145–153
Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC (1991) p53 expression in colorectal tumors. Am J Pathol 138:807–813
Shukla VK, Hughes DC, Hughes LE, McCormick F, Padua RA (1989)ras mutation in human melanotic lesions:K-ras activation is a frequent and early event in melanoma development. Oncogene Res 5:121–127
Sim CS, Slater SD, McKee PH (1992) Mutanat p53 protein is expressed in Bowen's disease. Am J Dermatopathol 14:195–199
Slater SD, McGrath JA, Hobbs C, Eady RA, McKee PH (1992) Expression of mutant p53 gene in squamous carcinoma arising in patients with recessive dystrophic epidermolysis bullosa. Histopathology 20:237–241
Strech JR, Gatter KC, Ralfkiaer E, Lane DP, Harris Al (1991) Expression of mutant p53 in malignant melanoma. Cancer Res 51:5976–5979
Tai T, Eisinger M, Ogata S, Lloyd KO (1983) Glycoproteins as differentiation markers in human malignant melanoma and melanocytes. Cancer Res 43:2773–2779
Takahashi H, Parsons PG (1990) In vitro phenotypic alteration of human melanoma cells induced by differentiating agents: heterogeneous effects on cellular growth and morphology, enzymatic activity, and antigenic expression. Pigm Cell Res 3:223–232
Takahashi H, Strutton GM, Parsons PG (1991a) Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody. Histopathology 18:221–227
Takahashi H, Schumann R, Quinn R, Briscoe TA, Parsons PG (1991b) Isomers of a marine diterpine distinguish sublines of human melanoma cells on the basis of apoptosis, cell cycle arrest and differentiation markers. Melanoma Res 1:359–366
Villuendes R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, Martinez JC, Martinez P (1992) p53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 166:235–241
Volkenandt M, Schlegel U, Nanus DM, Albino AP (1991) Mutational analysis of the human p53 gene in malignant melanoma. Pigm Cell Res 4:3540
Wynford-Thomas D (1991) Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour. J Pathol 165:187–201
Wynford-Thomas D (1992) p53 in tumour pathology: can we trust immunohistochemistry? J Pathol 166:320–330
Yamazaki Y, Murakami Y, Sekiya T, Ishihara K, Saida T (1992) Presentation at 91st annual meeting of Japanese Dermatological Association (abstract, in Japanese). Jpn J Dermatol 102:233
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamamoto, M., Takahashi, H. Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin. Vichows Archiv A Pathol Anat 422, 127–132 (1993). https://doi.org/10.1007/BF01607164
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01607164